🔗 Share this article

As America continues making historic changes to its vaccination schedules, an unexpected name appears somewhat surprisingly: Tracy Beth Høeg, an American of Danish descent sports physician and epidemiologist who initially gained attention by casting doubt on Covid shots throughout the global health crisis and has focused upon potential deaths following COVID-19 vaccination in her recent position at the Food and Drug Administration.

Planned Overhauls to Childhood Immunization Program

Agency leaders were set to announce radical revisions to the childhood immunization program recently, aligning the US with the Danish national calendar, sources say – a substantial departure that would put the US out of step with much of the world with no evidence for improved outcomes. The announcement has been postponed until the coming year.

Rather than the top vaccines chief, Tracy Beth Høeg is listed to present at the event. She was just designated temporary leader of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth appointee to lead the division this calendar year.

A New Direction at the Agency

The acting appointment could signify a strengthened alliance between the drug and vaccine divisions as Høeg and Prasad solidify control at the FDA – and it signals a increased emphasis upon dismantling long-standing vaccines at the FDA.

Høeg has repeatedly called for discontinuing some pediatric shot schedules in the US to become more in line with Denmark, a society with nationalized medicine and a citizenry about the population of Wisconsin’s.

To date statements, she has kept her attention on immunizations – usually the domain of Prasad, director of the FDA’s Center for Biologics Evaluation and Research (CBER) – rather than drug regulation.

Concerns Over Background

Høeg has no apparent track record in medication creation, oversight or administrative roles, which has been customary for former directors of the Center for Biologics Evaluation and Research. She has served at the FDA as a top consultant to the agency head and CBER since March.

“She doesn’t seem to have any of the qualifications” for leading the pharmaceutical oversight division, remarked Dr. Jonathan Howard. “She’s never run a randomized controlled trial. She has no expertise in leading a major agency. She is not an expert in industry regulation.”

Past heads of the center would “be deeply familiar with laws and regulations and the underlying principles of medication creation”, said a former acting FDA commissioner. “Objectively, she lacks the kind of background that former directors who led the center have had.”

The drug center has an immense range of responsibilities at the FDA, the former commissioner stated.

“Everybody just pays attention on the innovative therapies, but the off-patent medication office approves thousands of off-brand pharmaceuticals. There is also a biosimilars division, OTC medication office and so forth, and every single one need to be looked after,” Woodcock said. “The thing you overlook, that’s the thing that I always told people is going to cause problems.”

Additionally, a major administrative aspect to the role, which oversees in excess of 5,000 staff members. “It is a huge management job, if you perform it correctly,” Woodcock said.

Agency Reaction and Controversial Programs

In response to concerns about Høeg’s fitness for the role and whether this appointment indicates more teamwork among regulatory chiefs on immunizations, a representative responded that the “inquiries are based on incorrect presumptions”.

“Her experience aligns with the duties of her role,” the official stated, noting the time Dr. Høeg spent counseling the FDA commissioner on “drug safety and oversight research, including predictive safety algorithms and vaccine surveillance”.

As the temporary head, Dr. Høeg inherits the commissioner’s controversial expedited review system, a contentious expedited medication authorization process that allegedly concerned her predecessors. “How are these drugs being selected for this expedited pathway? Who is making the calls?” Howard questioned. “There’s a lot of lack of transparency happening at the agency right now.”

In general, he stated, “the Food and Drug Administration looks to be trending towards laxer regulations of most medications, with the exception of vaccines.”

Documented Past Work on Vaccines

With immunizations, Høeg has a more established, if concerning, history, critics said. She authored a research paper using unverified crowd-sourced reports to assess the rate of heart inflammation following Covid immunization. She consulted for the Florida surgeon general Joseph Ladapo, who allegedly have altered data to indicate Covid vaccines are riskier than they are.

Part of her “wish list” for the incoming federal leadership included revising guidelines for new vaccines and discontinuing “unnecessary” immunizations, she stated following the vote on a podcast. At the agency, Høeg has reportedly proposed excluding adolescent males from receiving Covid vaccinations.

“She is an complete dogmatist who starts off with her preconceived notions and reverse-engineers to retrofit the evidence in a highly disingenuous, dishonest manner,” Howard said.

Gaining Influence and a “Push for Payback”

Høeg joined fellow skeptics, {like|